- Home
- DAVA vs HUMA Comparison
DAVA vs HUMA Comparison
Compare DAVA & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DAVA | HUMA |
|---|---|---|
| Founded | 2000 | 2004 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.1M | 165.7M |
| IPO Year | 2015 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DAVA | HUMA |
|---|---|---|
| Price | $1.93 | $0.51 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $5.30 | $1.85 |
| AVG Volume (30 Days) | 748.8K | ★ 2.9M |
| Earning Date | 11-02-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,038,000.00 |
| Revenue This Year | N/A | $72.32 |
| Revenue Next Year | $1.35 | $518.79 |
| P/E Ratio | $20.02 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.60 | $0.53 |
| 52 Week High | $9.88 | $2.55 |
Technical Indicators
Market Signals| Indicator | DAVA | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 31.33 | 34.26 |
| Support Level | N/A | N/A |
| Resistance Level | $3.14 | $0.61 |
| Average True Range (ATR) | 0.17 | 0.03 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 18.09 | 9.05 |
Price Performance
Historical ComparisonAbout DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.
About HUMA Humacyte Inc.
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.